(Q67485532)

English

High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated

scientific article published on January 15, 1992

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

author name string

R. J. Motzer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

S. C. Gulati

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

J. P. Crown

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

S. Weisen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

M. Doherty

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

H. Herr

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

W. Fair

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

J. Sheinfeld

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

P. Sogani

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

P. Russo

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

11 September 2022

language of work or name

0 references

publication date

1 January 1992

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

15 January 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1309436

11 September 2022

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819920115%2969%3A2%3C550%3A%3AAID-CNCR2820690245%3E3.0.CO%3B2-D

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1309436

30 November 2023

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

69

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

550-556

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors

1

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

2

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors

3

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.

4

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors

5

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

6

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen

7

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979–1989)

9

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

10

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Autologous bone marrow transplantation for patients with poor-prognosis lymphoma

11

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis

15

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Prognostic factors for favorable outcome in disseminated germ cell tumors

16

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors

18

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors

19

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Venoocclusive disease of the liver following bone marrow transplantation

22

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors

23

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study

24

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

VP-16–213 salvage therapy for refractory germinal neoplasms

25

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Cancer Treatment Reports

26

71

197

author name string

Motzer

publication date

1987

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

27

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

28

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

29

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Cancer chemotherapy reports

30

58

709

author name string

Buckner

publication date

1974

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Comparative activity of ifosfamide and cyclophosphamide

31

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support

33

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.

34

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support

35

1 reference

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

https://api.crossref.org/works/10.1002/1097-0142(19920115)69:2%3C550::AID-CNCR2820690245%3E3.0.CO;2-D

30 November 2023

Identifiers

10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO;2-D

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1309436%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67485532&oldid=2020942480"